There are currently 69 clinical trials in Bradenton, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Meridien Research, Florida Clinical Research Center, LLC, Bradenton Research Centre and Bradenton Research Center, Inc. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/28/2025
Locations: Akero Clinical Study Site, Bradenton, Florida
Conditions: NASH With Fibrosis, MASH With Fibrosis
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Research Site, Bradenton, Florida +1 locations
Conditions: Viral Lung Infection and Acute Respiratory Failure
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/26/2025
Locations: Local Institution - 1015, Bradenton, Florida
Conditions: Psychosis Associated With Alzheimer's Disease
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/23/2025
Locations: Research Site, Bradenton, Florida
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/23/2025
Locations: Akero Clinical Study Site, Bradenton, Florida
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Local Institution - 001-922D, Bradenton, Florida
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/22/2025
Locations: Bradenton Research Center, Inc., Bradenton, Florida
Conditions: Alzheimer Disease, Early Onset
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
Recruiting
The goal of the Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study is to collect safety and performance data on the commercially available Shoulder iD™ Primary Reversed Glenoid device. The study will learn about standard device use in adult patients who have a functional deltoid muscle and massive and non-repairable rotator cuff tear. The main questions it aims to answer are: * What is the average improvement in patient-reported shoulder function after 2 years when compared to before... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Coastal Orthopedics, Bradenton, Florida
Conditions: Rotator Cuff Tears, Rheumatoid Arthritis Shoulder, Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus, Fracture, Humeral, Traumatic Arthritis of Right Shoulder Region (Diagnosis), Shoulder Deformity
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
05/22/2025
Locations: Bradenton Research Center, Inc., Bradenton, Florida
Conditions: Alzheimer Disease
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Recruiting
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS. 2. To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS 3. To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Bradenton Research Center Inc, Bradenton, Florida
Conditions: Sjögren's Syndrome (SS)
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Bradenton Research Center Inc, Bradenton, Florida
Conditions: Sjögren's Syndrome
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Local Institution - 007-922-D, Bradenton, Florida
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer